EUCTR2015-000402-19-GB进行中（未招募）1 期
An Adaptive Study of the Safety, Tolerability and Efficacy of Autologous ?d T Lymphocyte Therapy (ImmuniCell®) in Patients with Advanced Cancers which are Refractory to Current Treatment or who have Indolent Disease for which Immunotherapy may be Beneficial. - Autologous Gamma Delta T Cell Therapy (ImmuniCell®) in Advanced Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients aged =18 years
- •2.Performance status ECOG 0 or 1 (Appendix 1)
- •3.Subjects with histological or cytological confirmation of advanced malignant melanoma, renal cell carcinoma or NSCLC which are refractory to current standard treatments or who have indolent disease for which immunotherapy may be beneficial
- •4.Measurable disease according to the irRC criteria
- •5.Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted <2 weeks prior to Cycle 1:
- •a.Creatinine = 1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance = 50 ml/min
- •b.Total bilirubin = 1.5 x ULN
- •c.Alanine transaminase (ALT) and aspartate transaminase (AST) = 2.5 x ULN or = 5 x ULN with liver metastases
- •d.Absolute lymphocyte count =1.0 x 109/L
- •e.Absolute Neutrophil Count (ANC) =1.5 x 109/L
- •f.Platelets =100 x 109/L
- •g.Haemoglobin = 10 g/dL
- •6.Life expectancy of at least 3 months
- •7.Adequate increase in starting ?d T cell number to final ?d T cell number in the proliferation assay
- •8.Able to give informed, written consent
- •9.For female patients and female partners of male patients: must be surgically sterile, postmenopausal, or compliant with two forms of contraception (one of which must be a barrier method) during and for 6 months after the treatment period; female patients must have a negative urine pregnancy test at screening and must not be breast-feeding.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •1.Other primary cancers apart from non-melanoma skin cancers, carcinoma – in situ of the cervix, or a prior cancer treated with curative intent more than 2 years ago without any evidence or recurrent disease
- •2.Uncontrolled systemic infection
- •3.Systemic steroid therapy or other immune-suppressants (except in cases where the patient is receiving treatment with replacement doses for adrenal insufficiency)
- •4.Treatment with bisphosphonates, for instance zoledronate, in the previous 3 months or throughout the trial
- •5.New York Heart Association (NYHA) functional class =3 (Appendix 4) or myocardial infarction within 6 months
- •6.Clinically significant uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation not requiring therapy
- •7.Ulcerative Colitis / Inflammatory bowel disease, Addison’s disease
- •8.Pregnancy or lactation prior to or during the trial. A urine pregnancy test will be carried out at screening
- •9.Taking any other IMP or participation in another interventional clinical trial in the previous 30 days
- •10.Less than 4 weeks since systemic anti-cancer therapy (tyrosine kinase inhibitors, chemotherapy, immunotherapy, hormonal therapy, radiotherapy) and more than 6 weeks since mitomycin C and nitrosureas
- •11.Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the trial or evaluation of the trial results
- •12.Any other condition considered by a trial physician to be inappropriate for inclusion to the study such as contraindications to leukapheresis (contraindications to heparin which are: recent cerebral haemorrhage; peptic ulcer; recent surgery to eye or nervous system; hypersensitivity to heparin; past history of Type II heparin induced thrombocytopenia; past history of significant spontaneous haemorrhage; known haemophilia or other bleeding disorder)
- •13.Serological evidence of active infection with HIV, hepatitis B/C, HTLV and syphilis.
研究者
相似试验
已完成
不适用
ImmuniCell® in patients with advanced cancerson small-cell lung cancer, renal cell carcinoma and malignant melanomaCancerISRCTN26113637TC BioPharm48
尚未招募
不适用
Observational Study of the Safety, Tolerability and Efficacy of Cannabidiol Oro-buccal Sprays for Treating Pain and/or StressChronic pain or pain associated with chronic conditions appropriate for management with cannabidiolStress conditions appropriate for management with cannabidiolMental Health - Other mental health disordersAnaesthesiology - Pain managementACTRN12622001137785Medlab Clinical Ltd2,000
尚未招募
不适用
Observational Study of the Safety, Tolerability and Efficacy of cannabis-based medicineChronic PainCancer - Any cancerInflammatory and Immune System - Rheumatoid arthritisInjuries and Accidents - Other injuries and accidentsMusculoskeletal - Other muscular and skeletal disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonPublic Health - Other public healthACTRN12622001133729Medlab Clinical Ltd1,000
进行中（未招募）
1 期
A study evaluating the efficacy, safety and tolerability of Nangibotide in patients with Covid-19.Covid-19MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-001504-42-FRINOTREM S.A.60
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part AChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000115538Enliven Therapeutics, Inc.15